One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Search from 250 M+ research papersSearch from 250 M+ research papers
Open Accesshttps://doi.org/10.1093/annonc/mdz453.003
Copy DOI Journal: Annals of Oncology |  Publication Date: Dec 1, 2019 |
 Citations: 2 |  License type: publisher-specific-oa |
Affiliation: Charles University, Okayama University Hospital, Ospedale Vincenzo Cervello, AstraZeneca (United Kingdom), University of California, Los Angeles, Odessa National Medical University, AstraZeneca (United States), Semmelweis University, Samsung (South Korea), Sungkyunkwan University, Institute of Oncology NN Petrov, Hospital Universitario 12 De Octubre, Hematology Oncology Consultants, Kyiv City Clinical Oncology Center, Asklepios, Budgetary Health Care Institution of the Omsk Region "Clinical Oncology Center", Istanbul University-Cerrahpaşa, Karl Landsteiner SocietyLBA2 First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC: Safety, pharmacokinetics (PK) and immunogenicity in CASPIAN
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
